Answer
Nivolumab + relatlimab are therapeutic IgG4 monoclonal antibodies expected to be broken down into small peptides, amino acids and small carbohydrates by lysosomes or receptor-mediated endocytosis.
Sources for this answer
- Opdualag 240 mg/80 mg concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 6Document updated
Sources checked